

INTRODUCING THE FIRST ORAL, ONCE-DAILY DIRECT FACTOR Xa INHIBITOR

Xarelto®: Simply Protecting More Patients

Compelling evidence of superior protection against DVT, PE, and death, with safety comparable to enoxaparin^{1, 2, 4-7}

SIMPLICITY

THAT IS ONCE DAILY

- One 10-mg tablet, once daily³
- No dose adjustment necessary³



EFFICACY

THAT IS SUPERIOR

- Significant reduction vs enoxaparin in total DVT/PE^{2, 4-7}

SAFETY

THAT IS DEPENDABLE

- Good safety profile including a low rate of major bleeding^{1, 4-7}
- No evidence of drug-induced liver injury attributable to Xarelto^{1, 4-7}

PROTECTION

THAT GIVES CONFIDENCE

- Ensures patients are protected from hospital to home³

...in adult patients undergoing elective hip knee replacement surgery.

References: 1. Eriksson BI, Kakkar AG, Turpie AGG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. *J Bone Joint Surg [Br]*. 2009;91(5):636-644. 2. In RECORD2 long-term treatment with rivaroxaban has been compared vs. short-term treatment with enoxaparin. 3. Xarelto [summary of product characteristics]. Leverkusen Germany: Bayer HealthCare AG; January 2011. 4. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358(26):2765-2775. 5. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008;372:29-37. 6. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358(26):2776-2786. 7. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009;373(9676):1673-1680.